Cannabinoids and Dementia: A Review of Clinical and Preclinical Data
The endocannabinoid system has been shown to be associated with neurodegenerative diseases and dementia. We review the preclinical and clinical data on cannabinoids and four neurodegenerative diseases: Alzheimer's disease (AD), Huntington's disease (HD), Parkinson's disease (PD) and v...
Saved in:
Main Authors: | Michael Halpern (Author), Sebastian Walther (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2010-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents
by: Daniel A. Ladin, et al.
Published: (2016) -
Corrigendum: Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents
by: Daniel A. Ladin, et al.
Published: (2021) -
Cannabinoids in Integumentary Wound Care: A Systematic Review of Emerging Preclinical and Clinical Evidence
by: Dhakshila Niyangoda, et al.
Published: (2024) -
Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia: a systematic review
by: Jodie Belinda Hillen, et al.
Published: (2019) -
IUPHAR review- Preclinical models of neuropathic pain: Evaluating multifunctional properties of natural cannabinoid receptors ligands
by: Khalid Benamar
Published: (2024)